Lipocine (LPCN) Competitors $3.11 +0.10 (+3.32%) Closing price 03:59 PM EasternExtended Trading$3.11 0.00 (-0.13%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPCN vs. IMMX, QNTM, OSTX, MNOV, GNTA, CUE, ANL, GANX, CVM, and HOWLShould you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Immix Biopharma (IMMX), Quantum Biopharma (QNTM), OS Therapies (OSTX), MediciNova (MNOV), Genenta Science (GNTA), Cue Biopharma (CUE), Adlai Nortye (ANL), Gain Therapeutics (GANX), CEL-SCI (CVM), and Werewolf Therapeutics (HOWL). These companies are all part of the "pharmaceutical products" industry. Lipocine vs. Its Competitors Immix Biopharma Quantum Biopharma OS Therapies MediciNova Genenta Science Cue Biopharma Adlai Nortye Gain Therapeutics CEL-SCI Werewolf Therapeutics Immix Biopharma (NASDAQ:IMMX) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation. Do institutionals & insiders believe in IMMX or LPCN? 11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 55.4% of Immix Biopharma shares are held by company insiders. Comparatively, 6.4% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, IMMX or LPCN? Immix Biopharma has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Is IMMX or LPCN more profitable? Lipocine's return on equity of -23.59% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Immix BiopharmaN/A -205.35% -110.63% Lipocine N/A -23.59%-21.91% Which has higher valuation & earnings, IMMX or LPCN? Lipocine has higher revenue and earnings than Immix Biopharma. Lipocine is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmix BiopharmaN/AN/A-$21.61M-$0.77-2.84Lipocine$11.20M1.51$10K-$0.87-3.57 Does the media prefer IMMX or LPCN? In the previous week, Lipocine had 10 more articles in the media than Immix Biopharma. MarketBeat recorded 10 mentions for Lipocine and 0 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.00 beat Lipocine's score of -0.80 indicating that Immix Biopharma is being referred to more favorably in the media. Company Overall Sentiment Immix Biopharma Neutral Lipocine Negative Do analysts prefer IMMX or LPCN? Immix Biopharma currently has a consensus target price of $7.00, indicating a potential upside of 219.63%. Lipocine has a consensus target price of $9.00, indicating a potential upside of 189.39%. Given Immix Biopharma's higher probable upside, equities analysts clearly believe Immix Biopharma is more favorable than Lipocine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Lipocine 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryLipocine beats Immix Biopharma on 8 of the 14 factors compared between the two stocks. Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPCN vs. The Competition Export to ExcelMetricLipocineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.31M$2.51B$5.76B$9.59BDividend YieldN/A1.67%4.41%4.09%P/E Ratio-3.575.3022.4021.92Price / Sales1.51752.08472.14121.31Price / CashN/A180.4637.7358.48Price / Book0.985.939.536.61Net Income$10K$31.83M$3.26B$265.56M7 Day Performance2.64%1.80%2.11%1.98%1 Month Performance-4.60%4.36%5.12%1.33%1 Year Performance-16.17%11.44%31.25%21.15% Lipocine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPCNLipocine2.8326 of 5 stars$3.11+3.3%$9.00+189.4%-15.9%$16.31M$11.20M-3.5710News CoverageAnalyst ForecastAnalyst RevisionIMMXImmix Biopharma3.2701 of 5 stars$2.30+1.3%$7.00+204.3%+0.0%$65.45MN/A-2.999QNTMQuantum BiopharmaN/A$20.61-8.2%N/AN/A$65.27MN/A-1.47N/AOSTXOS Therapies2.232 of 5 stars$2.18+5.8%$18.00+725.7%-40.0%$65.15MN/A-2.53N/AAnalyst ForecastGap UpMNOVMediciNova2.352 of 5 stars$1.31flat$7.00+434.4%+6.6%$64.25M$1M-5.2410Positive NewsGNTAGenenta Science1.9033 of 5 stars$3.57+2.1%$25.00+599.5%-15.8%$64.10MN/A0.007Positive NewsGap UpCUECue Biopharma2.6826 of 5 stars$0.82-0.9%$4.00+388.5%-10.4%$63.47M$9.29M-1.4660News CoverageANLAdlai Nortye1.4372 of 5 stars$1.77+4.8%$9.00+408.2%-43.7%$62.36M$5M0.00127Gap UpGANXGain Therapeutics2.6411 of 5 stars$1.77+2.3%$7.80+340.7%+34.1%$62.19M$50K-2.8120High Trading VolumeCVMCEL-SCI1.461 of 5 stars$8.92+2.5%N/A-73.1%$61.39MN/A-18.5843Positive NewsHOWLWerewolf Therapeutics3.3119 of 5 stars$1.33flat$8.33+526.6%-42.3%$60.82M$1.88M-0.8140Analyst Forecast Related Companies and Tools Related Companies IMMX Alternatives QNTM Alternatives OSTX Alternatives MNOV Alternatives GNTA Alternatives CUE Alternatives ANL Alternatives GANX Alternatives CVM Alternatives HOWL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPCN) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access